Company

Novartis Raises Full-Year Core Profit Guidance as Q3 Sales Grow 4% – Kisqali Surges 37% to Lead Priority Brands
Finanical ReportsNovartis

Novartis Raises Full-Year Core Profit Guidance as Q3 Sales Grow 4% – Kisqali Surges 37% to Lead Priority Brands

Novartis AG (NYSE: NVS) reported third-quarter 2026 results, with net sales of USD 14.52 billion, up 4% year on year (also +4% in constant currencies, "cc"), and core operating income…

Genentech's Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

Genentech’s Divarasib Beats Standard‑of‑Care KRAS G12C Inhibitors in Pivotal Phase III Krascendo 1 Study – Superior OS and 42 % Lower Risk of Progression or Death in Pretreated KRAS G12C‑Mutant NSCLC

HutchMed's Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

HutchMed’s Global Phase III SAFFRON Study Hits Primary Endpoint – ORPATHYS (Savolitinib) Plus TAGRISSO Cuts Progression or Death Risk by 45 % vs Chemotherapy in EGFR‑Mutated NSCLC After Osimertinib Progression

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity
Clinical trial resultsHKG: 2480

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC
ADC / XDCClinical trial approval / initiation

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler
BiotechChance Pharmaceuticals

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform
Cell-therapyNYSE: TAK

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Show More